Immatics N.V. (NASDAQ:IMTX) Receives $18.80 Average PT from Analysts

Shares of Immatics N.V. (NASDAQ:IMTX) have been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $18.80.

IMTX has been the subject of several research analyst reports. Leerink Partners reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of Immatics in a research report on Thursday, December 4th. Mizuho raised their price target on shares of Immatics from $19.00 to $23.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Wall Street Zen downgraded shares of Immatics from a “hold” rating to a “sell” rating in a research note on Sunday. Zacks Research raised shares of Immatics from a “strong sell” rating to a “hold” rating in a report on Monday, October 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a research note on Wednesday, October 8th.

Institutional Investors Weigh In On Immatics

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE increased its holdings in Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after buying an additional 2,231 shares during the period. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Immatics by 8.3% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 47,635 shares of the company’s stock valued at $406,000 after acquiring an additional 3,666 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Immatics by 28.7% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 31,894 shares of the company’s stock valued at $172,000 after acquiring an additional 7,116 shares during the last quarter. Vontobel Holding Ltd. acquired a new stake in shares of Immatics in the second quarter worth $59,000. Finally, Insigneo Advisory Services LLC purchased a new position in shares of Immatics during the third quarter worth $103,000. Institutional investors and hedge funds own 64.41% of the company’s stock.

Immatics Price Performance

Immatics stock opened at $9.17 on Thursday. Immatics has a 1-year low of $3.30 and a 1-year high of $12.41. The business has a fifty day moving average price of $10.06 and a 200-day moving average price of $8.13. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -8.99 and a beta of 1.36.

Immatics (NASDAQ:IMTX) last released its quarterly earnings results on Monday, November 17th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.01. The company had revenue of $6.10 million during the quarter, compared to analysts’ expectations of $12.53 million. Immatics had a negative return on equity of 24.16% and a negative net margin of 146.13%. On average, equities research analysts anticipate that Immatics will post -0.72 earnings per share for the current fiscal year.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.